Source
Pharmaphorum
Potential antibody therapies from AstraZeneca and Regeneron for light chain (AL) amyloidosis had new data at ASCO, raising the prospect of new treatments for the rare bone marrow disease.
In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together into amyloid fibrils that are deposited in organs and tissues, causing damage and a wide range of debilitating symptoms.
News Url